Tacton Launches Connect to Anything, Powered by Workato, Simplifying Integration for Manufacturers
21.1.2025 15:06:00 CET | Business Wire | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and leading SaaS platform simplifying sales and configuration processes for manufacturers of complex products, today announced the launch of its Connect to Anything integration capability, powered by Workato, the leading enterprise orchestration platform. This innovative solution transforms how manufacturers integrate Tacton CPQ into their digital ecosystems, enabling seamless connections to over 600 enterprise applications, including CRM, ERP, PLM, PIM, and analytics tools.
Manufacturers often face costly inefficiencies from data silos and integration roadblocks as IT teams struggle to keep pace with complex connections. The stakes are high: poor data quality costs organizations an average of $12.9 million annually, according to Gartner’s® 2020 Magic Quadrant™ for Data Quality Solutions. Connect to Anything solves this challenge by making it simple to connect data across applications without heavy reliance on IT. With pre-built connectors, reusable recipes, and a no-code approach, Tacton empowers manufacturers to eliminate silos, streamline workflows, and accelerate their digital transformation journey.
“As manufacturers embrace digital transformation, seamless integration across systems has become mission-critical,” saidJesper Alfredsson, Chief Product Officer, Tacton. “Connect to Anything simplifies this process by enabling manufacturers to unify their digital ecosystems, reduce IT dependency, and achieve faster, smarter operations that drive tangible business outcomes.”
With Connect to Anything, manufacturers can:
- Simplify Integration: Seamlessly connect Tacton CPQ to essential systems with pre-built connectors and no-code recipes.
- Accelerate ROI: Achieve faster implementation and operational efficiency with reduced dependency on IT.
- Maximize CPQ Value: Unlock greater returns from CPQ investments with integration capabilities available from the start of implementation.
Connect to Anything brings together unmatched innovation through this partnership. Tacton has been recognized as a Leader in the Gartner® Magic Quadrant™ for CPQ Applications, while Workato is a Leader in the Gartner® Magic Quadrant™ for Integration Platform as a Service (iPaaS). Together, these industry leaders deliver a powerful solution that helps manufacturers simplify integrations, optimize workflows, and scale operations seamlessly.
“We are thrilled to partner with Tacton, providing manufacturers with seamless integration capabilities that accelerate their journey towards smart factories,” said Nam Le, General Manager of Workato’s Embed Business. “This collaboration exemplifies how leaders in their respective industries can drive powerful outcomes for manufacturers. By embedding Workato’s no-code platform into Tacton CPQ, manufacturers gain unmatched flexibility and efficiency in connecting and optimizing their digital ecosystems. Together, we’re empowering manufacturers to build connected, agile operations that deliver real business value.”
Connect to Anything is available now for manufacturers looking to simplify and accelerate their digital transformation. To learn more about our integration capabilities, visit our website.
About Tacton
Tacton is a leading SaaS company redefining how manufacturers of complex products engage with their buyers. Its cutting-edge buyer engagement platform empowers manufacturers to streamline the buyer journey, deliver personalized, customer-centric experiences, and bring complex products to market faster and more efficiently.
Recognized as a Leader in Gartner’s® Magic Quadrant™ for CPQ Applications, Tacton partners with manufacturers to drive smart factory initiatives and align operations with customer needs. With over 25 years of experience and trusted by more than 100 global leaders like ABB, Daimler, MAN, Scania, Siemens, Xylem, and Yaskawa, Tacton is co-headquartered in Chicago and Stockholm, with regional offices in Karlsruhe, Warsaw, and Tokyo. Learn more at www.tacton.com.
About Workato
Workato transforms technology complexity into business opportunity. As the leader in enterprise orchestration, Workato helps businesses globally streamline operations by connecting data, processes, applications, and experiences. Its AI-powered platform enables teams to navigate complex workflows in real time, driving efficiency and agility. Trusted by a community of 400,000 global users, Workato empowers organizations of every size to unlock new value and lead in today’s fast-changing world. Learn how Workato helps businesses of all sizes achieve more at www.workato.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116707013/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom